Anti-CD20X anti-CD28 combination therapy

By developing anti-CD20 x anti-CD28 antibodies that bind to CD28 on T cells and CD20 on B cells, the attack capability of T cells against B-cell malignancies is enhanced, solving the problem of targeting and activating T cells in existing methods and achieving effective treatment of B-cell malignancies.

CN122094983APending Publication Date: 2026-05-26XENCOR INC +1
View PDF 22 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
XENCOR INC
Filing Date
2024-08-28
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Existing antibody-based therapies struggle to effectively target and kill CD20-expressing cancer cells, especially B-cell malignancies, and lack safe drug components to activate T-cell attacks against cancer cells.

Method used

Anti-CD20 x anti-CD28 antibodies were developed, which enhance the ability of T cells to attack cancer cells by binding to CD28 co-stimulatory molecules on T cells and CD20 on B cells, and can be combined with other T cell linker antibodies for the treatment of B cell malignancies.

Benefits of technology

It achieves specific targeting and effective killing of B-cell malignancies, enhances the activation and killing ability of T cells against cancer cells, and provides a safe drug composition to activate the immune system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122094983A_ABST
    Figure CN122094983A_ABST
Patent Text Reader

Abstract

Provided herein are novel anti-CD20x anti-CD28 antibodies and methods of using such antibodies to treat B cell malignancies. The subject anti-CD20x anti-CD28 antibodies are capable of agonically binding to a CD28 costimulatory molecule on a T cell and to CD20 on a tumor cell. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in the treatment of B-cell malignancies in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies).
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Commissioning in multi-hop networks by using a single-hop connection

    US11191125B2

  • Methods of generating variant proteins with increased host string content and compositions thereof

    US20060008883A1

  • Fc variants with optimized properties

    US20060235208A1

  • Fc Variants With Optimized Fc Receptor Binding Properties

    US20070148170A1

  • Fc VARIANTS WITH ALTERED BINDING TO FcRn

    US20090163699A1